Organisation paid for research Program year 2025 Source: CMS Open Payments

Covance Central Laboratory Services

Neither a doctor nor a teaching hospital

Research payments

$260,230

12 payments

Through program year 2025, Covance Central Laboratory Services is reported as receiving $260,230 in research payments, across 12 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$38,397	1
2024	Research	$48,953	2
2023	Research	$106,126	6
2022	Research	$66,753	3

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $257,115 11 payments
Celgene Corporation $3,115 1 payment

Studies the money was for Research payments · program years 2022–2025

DDI Study CYP3A4/p-gp (victim) Inhibitor - An Open-label, Randomized, 2-Period Crossover Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose Pharmacokinetics of Danicamtiv in Healthy Participants $74,140 2 payments
SAD MAD Combo - A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986209 in Healthy Participants $73,544 1 payment
ECOG Phase III RCC peri- Adjuvant - A Phase III clinical trial conducted by the Eastern Cooperative Oncology Group to assess peri-adjuvant treatment strategies for patients with renal cell carcinoma. (ECOG Phase III RCC peri- Adjuvant) $60,667 3 payments
ECOG Phase III RCC Adjuvant A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) $38,397 1 payment
Ph I Pk multitumor SubQ formulation Relatlimab $5,394 2 payments
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants $4,967 1 payment
Ph1 mCRPC (CC-90011-PCA-001) - A phase 1, open-label, functional imaging study to assess whether CC-90011 reverses the castration resistance due to lineage switch in participants with metastatic castration-resistant prostate cancer (mCRPC) who have failed $3,115 1 payment
DDI (ASA followup) - A Randomized, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986177 (an Oral Antithrombotic) With Single and Dual Antiplatelet Therapy (Aspirin and Clopidogrel) in Healthy Particip $5 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.